Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicentre, Double-blind, Randomised, Dose Range Finding Placebo Controlled Study of Rifaximin-EIR Tablet: Clinical Effectiveness and Tolerability in the Treatment of Moderate, Active Crohn's Disease

NCT00528073 is registered in ClinicalTrials.gov with Alfasigma S.p.A. as lead sponsor.

NCT NCT00528073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00528073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicentre, Double-blind, Randomised, Dose Range Finding Placebo Controlled Study of Rifaximin-EIR Tablet: Clinical Effectiveness and Tolerability in the Treatment of Moderate, Active Crohn's Disease
Lead sponsor
Alfasigma S.p.A.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
October 31, 2009
Enrollment
410 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease